A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses

David Cameron, Michelle Casey, Michael Press, Deborah Lindquist, Tadeusz Pienkowski, C. Gilles Romieu, Stephen Chan, Agnieszka Jagiello-Gruszfeld, Bella Kaufman, John Crown, Arlene Chan, Mario Campone, Patrice Viens, Neville Davidson, Vera Gorbounova, Johannes Isaac Raats, Dimosthenis Skarlos, Beth Newstat, Debasish Roychowdhury, Paolo PaolettiCristina Oliva, Stephen Rubin, Steven Stein, Charles E. Geyer

Research output: Contribution to journalArticle

596 Citations (Scopus)

Abstract

Purpose: Lapatinib is a small molecule, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER2). Initial results of a phase III trial demonstrated that lapatinib plus capecitabine is superior to capecitabine alone in women with HER2-positive advanced breast cancer that progressed following prior therapy including trastuzumab. Updated efficacy and initial biomarker results from this trial are reported. Methods: Women with HER2-positive, locally advanced or metastatic breast cancer previously treated with anthracycline-, taxane-, and trastuzumab-containing regimens were randomized to lapatinib 1,250 mg/day continuously plus capecitabine 2,000 mg/m2 days 1-14 of a 21-day cycle or capecitabine 2,500 mg/m2 on the same schedule. The primary endpoint was time to progression (TTP) as determined by an independent review panel. Relationship between progression-free survival (PFS) and tumor HER2 expression and serum levels of HER2 extracellular domain (ECD) were assessed. Results: 399 women were randomized. The addition of lapatinib prolonged TTP with a hazard ratio (HR) of 0.57 (95% CI, 0.43-0.77; P < 0.001) and provided a trend toward improved overall survival (HR: 0.78, 95% CI: 0.55-1.12, P = 0.177), and fewer cases with CNS involvement at first progression (4 vs. 13, P = 0.045). Baseline serum HER2 ECD did not predict for benefit from lapatinib. Conclusion: The addition of lapatinib to capecitabine provides superior efficacy for women with HER2-positive, advanced breast cancer progressing after treatment with anthracycline-, taxane-, and trastuzumab-based therapy. Biomarker studies could not identify a subgroup of patients who failed to benefit from the addition of lapatinib to capecitabine.

Original languageEnglish (US)
Pages (from-to)533-543
Number of pages11
JournalBreast Cancer Research and Treatment
Volume112
Issue number3
DOIs
StatePublished - Dec 2008

Fingerprint

Biomarkers
Breast Neoplasms
Anthracyclines
Capecitabine
Trastuzumab
lapatinib
Serum
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Disease-Free Survival
Appointments and Schedules
Therapeutics
Survival
Neoplasms
taxane

Keywords

  • Advanced breast cancer
  • Biomarker
  • Capecitabine
  • Dual tyrosine kinase inhibitor
  • HER2-positive
  • Lapatinib
  • Metastatic breast cancer
  • Phase III

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab : Updated efficacy and biomarker analyses. / Cameron, David; Casey, Michelle; Press, Michael; Lindquist, Deborah; Pienkowski, Tadeusz; Romieu, C. Gilles; Chan, Stephen; Jagiello-Gruszfeld, Agnieszka; Kaufman, Bella; Crown, John; Chan, Arlene; Campone, Mario; Viens, Patrice; Davidson, Neville; Gorbounova, Vera; Raats, Johannes Isaac; Skarlos, Dimosthenis; Newstat, Beth; Roychowdhury, Debasish; Paoletti, Paolo; Oliva, Cristina; Rubin, Stephen; Stein, Steven; Geyer, Charles E.

In: Breast Cancer Research and Treatment, Vol. 112, No. 3, 12.2008, p. 533-543.

Research output: Contribution to journalArticle

Cameron, D, Casey, M, Press, M, Lindquist, D, Pienkowski, T, Romieu, CG, Chan, S, Jagiello-Gruszfeld, A, Kaufman, B, Crown, J, Chan, A, Campone, M, Viens, P, Davidson, N, Gorbounova, V, Raats, JI, Skarlos, D, Newstat, B, Roychowdhury, D, Paoletti, P, Oliva, C, Rubin, S, Stein, S & Geyer, CE 2008, 'A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses', Breast Cancer Research and Treatment, vol. 112, no. 3, pp. 533-543. https://doi.org/10.1007/s10549-007-9885-0
Cameron, David ; Casey, Michelle ; Press, Michael ; Lindquist, Deborah ; Pienkowski, Tadeusz ; Romieu, C. Gilles ; Chan, Stephen ; Jagiello-Gruszfeld, Agnieszka ; Kaufman, Bella ; Crown, John ; Chan, Arlene ; Campone, Mario ; Viens, Patrice ; Davidson, Neville ; Gorbounova, Vera ; Raats, Johannes Isaac ; Skarlos, Dimosthenis ; Newstat, Beth ; Roychowdhury, Debasish ; Paoletti, Paolo ; Oliva, Cristina ; Rubin, Stephen ; Stein, Steven ; Geyer, Charles E. / A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab : Updated efficacy and biomarker analyses. In: Breast Cancer Research and Treatment. 2008 ; Vol. 112, No. 3. pp. 533-543.
@article{3af812f5f8db4972a989a488cbf72eda,
title = "A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses",
abstract = "Purpose: Lapatinib is a small molecule, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER2). Initial results of a phase III trial demonstrated that lapatinib plus capecitabine is superior to capecitabine alone in women with HER2-positive advanced breast cancer that progressed following prior therapy including trastuzumab. Updated efficacy and initial biomarker results from this trial are reported. Methods: Women with HER2-positive, locally advanced or metastatic breast cancer previously treated with anthracycline-, taxane-, and trastuzumab-containing regimens were randomized to lapatinib 1,250 mg/day continuously plus capecitabine 2,000 mg/m2 days 1-14 of a 21-day cycle or capecitabine 2,500 mg/m2 on the same schedule. The primary endpoint was time to progression (TTP) as determined by an independent review panel. Relationship between progression-free survival (PFS) and tumor HER2 expression and serum levels of HER2 extracellular domain (ECD) were assessed. Results: 399 women were randomized. The addition of lapatinib prolonged TTP with a hazard ratio (HR) of 0.57 (95{\%} CI, 0.43-0.77; P < 0.001) and provided a trend toward improved overall survival (HR: 0.78, 95{\%} CI: 0.55-1.12, P = 0.177), and fewer cases with CNS involvement at first progression (4 vs. 13, P = 0.045). Baseline serum HER2 ECD did not predict for benefit from lapatinib. Conclusion: The addition of lapatinib to capecitabine provides superior efficacy for women with HER2-positive, advanced breast cancer progressing after treatment with anthracycline-, taxane-, and trastuzumab-based therapy. Biomarker studies could not identify a subgroup of patients who failed to benefit from the addition of lapatinib to capecitabine.",
keywords = "Advanced breast cancer, Biomarker, Capecitabine, Dual tyrosine kinase inhibitor, HER2-positive, Lapatinib, Metastatic breast cancer, Phase III",
author = "David Cameron and Michelle Casey and Michael Press and Deborah Lindquist and Tadeusz Pienkowski and Romieu, {C. Gilles} and Stephen Chan and Agnieszka Jagiello-Gruszfeld and Bella Kaufman and John Crown and Arlene Chan and Mario Campone and Patrice Viens and Neville Davidson and Vera Gorbounova and Raats, {Johannes Isaac} and Dimosthenis Skarlos and Beth Newstat and Debasish Roychowdhury and Paolo Paoletti and Cristina Oliva and Stephen Rubin and Steven Stein and Geyer, {Charles E.}",
year = "2008",
month = "12",
doi = "10.1007/s10549-007-9885-0",
language = "English (US)",
volume = "112",
pages = "533--543",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab

T2 - Updated efficacy and biomarker analyses

AU - Cameron, David

AU - Casey, Michelle

AU - Press, Michael

AU - Lindquist, Deborah

AU - Pienkowski, Tadeusz

AU - Romieu, C. Gilles

AU - Chan, Stephen

AU - Jagiello-Gruszfeld, Agnieszka

AU - Kaufman, Bella

AU - Crown, John

AU - Chan, Arlene

AU - Campone, Mario

AU - Viens, Patrice

AU - Davidson, Neville

AU - Gorbounova, Vera

AU - Raats, Johannes Isaac

AU - Skarlos, Dimosthenis

AU - Newstat, Beth

AU - Roychowdhury, Debasish

AU - Paoletti, Paolo

AU - Oliva, Cristina

AU - Rubin, Stephen

AU - Stein, Steven

AU - Geyer, Charles E.

PY - 2008/12

Y1 - 2008/12

N2 - Purpose: Lapatinib is a small molecule, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER2). Initial results of a phase III trial demonstrated that lapatinib plus capecitabine is superior to capecitabine alone in women with HER2-positive advanced breast cancer that progressed following prior therapy including trastuzumab. Updated efficacy and initial biomarker results from this trial are reported. Methods: Women with HER2-positive, locally advanced or metastatic breast cancer previously treated with anthracycline-, taxane-, and trastuzumab-containing regimens were randomized to lapatinib 1,250 mg/day continuously plus capecitabine 2,000 mg/m2 days 1-14 of a 21-day cycle or capecitabine 2,500 mg/m2 on the same schedule. The primary endpoint was time to progression (TTP) as determined by an independent review panel. Relationship between progression-free survival (PFS) and tumor HER2 expression and serum levels of HER2 extracellular domain (ECD) were assessed. Results: 399 women were randomized. The addition of lapatinib prolonged TTP with a hazard ratio (HR) of 0.57 (95% CI, 0.43-0.77; P < 0.001) and provided a trend toward improved overall survival (HR: 0.78, 95% CI: 0.55-1.12, P = 0.177), and fewer cases with CNS involvement at first progression (4 vs. 13, P = 0.045). Baseline serum HER2 ECD did not predict for benefit from lapatinib. Conclusion: The addition of lapatinib to capecitabine provides superior efficacy for women with HER2-positive, advanced breast cancer progressing after treatment with anthracycline-, taxane-, and trastuzumab-based therapy. Biomarker studies could not identify a subgroup of patients who failed to benefit from the addition of lapatinib to capecitabine.

AB - Purpose: Lapatinib is a small molecule, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER2). Initial results of a phase III trial demonstrated that lapatinib plus capecitabine is superior to capecitabine alone in women with HER2-positive advanced breast cancer that progressed following prior therapy including trastuzumab. Updated efficacy and initial biomarker results from this trial are reported. Methods: Women with HER2-positive, locally advanced or metastatic breast cancer previously treated with anthracycline-, taxane-, and trastuzumab-containing regimens were randomized to lapatinib 1,250 mg/day continuously plus capecitabine 2,000 mg/m2 days 1-14 of a 21-day cycle or capecitabine 2,500 mg/m2 on the same schedule. The primary endpoint was time to progression (TTP) as determined by an independent review panel. Relationship between progression-free survival (PFS) and tumor HER2 expression and serum levels of HER2 extracellular domain (ECD) were assessed. Results: 399 women were randomized. The addition of lapatinib prolonged TTP with a hazard ratio (HR) of 0.57 (95% CI, 0.43-0.77; P < 0.001) and provided a trend toward improved overall survival (HR: 0.78, 95% CI: 0.55-1.12, P = 0.177), and fewer cases with CNS involvement at first progression (4 vs. 13, P = 0.045). Baseline serum HER2 ECD did not predict for benefit from lapatinib. Conclusion: The addition of lapatinib to capecitabine provides superior efficacy for women with HER2-positive, advanced breast cancer progressing after treatment with anthracycline-, taxane-, and trastuzumab-based therapy. Biomarker studies could not identify a subgroup of patients who failed to benefit from the addition of lapatinib to capecitabine.

KW - Advanced breast cancer

KW - Biomarker

KW - Capecitabine

KW - Dual tyrosine kinase inhibitor

KW - HER2-positive

KW - Lapatinib

KW - Metastatic breast cancer

KW - Phase III

UR - http://www.scopus.com/inward/record.url?scp=56549113680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56549113680&partnerID=8YFLogxK

U2 - 10.1007/s10549-007-9885-0

DO - 10.1007/s10549-007-9885-0

M3 - Article

C2 - 18188694

AN - SCOPUS:56549113680

VL - 112

SP - 533

EP - 543

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -